Global pannexin 1 deletion increases tumor‐infiltrating lymphocytes in the BRAF /Pten mouse melanoma model
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Rafael E Sanchez-Pupo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, Western University, London, Canada. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Immunotherapies for malignant melanoma seek to boost the anti‐tumoral response of CD8 + T cells, but have a limited patient response rate, in part due to limited tumoral immune cell infiltration. Genetic or pharmacological inhibition of the pannexin 1 (PANX1) channel‐forming protein is known to decrease melanoma cell tumorigenic properties in vitro and ex vivo . Here, we crossed Panx1 knockout ( Panx1 −/− ) mice with the inducible melanoma model Braf CA , Pten loxP , Tyr::CreER T2 (BPC). We found that deleting the Panx1 gene in mice does not reduce BRAF(V600E)/Pten‐driven primary tumor formation or improve survival. However, tumors in BPC‐ Panx1 −/− mice exhibited a significant increase in the infiltration of CD8 + T lymphocytes, with no changes in the expression of early T‐cell activation marker CD69, lymphocyte activation gene 3 protein (LAG‐3) checkpoint receptor, or programmed cell death ligand‐1 (PD‐L1) in tumors when compared to the BPC‐ Panx1 +/+ genotype. Our results suggest that, although Panx1 deletion does not overturn the aggressive BRAF / Pten ‐driven melanoma progression in vivo , it does increase the infiltration of effector immune T‐cell populations in the tumor microenvironment. We propose that PANX1‐targeted therapy could be explored as a strategy to increase tumor‐infiltrating lymphocytes to boost anti‐tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, Western University, London, Canada.
- Department of Microbiology and Immunology, Western University, London, Canada.
- Department of Physiology and Pharmacology, Western University, London, Canada.
- Division of Experimental Oncology, Department of Oncology, Schulich School of Medicine and Dentistry, Western University, London, Canada.
ORCID-Profile: Rafael E Sanchez-Pupo, Silvia Penuela
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Sanchez-Pupo, R. E., Finch, G. A., Johnston, D. E., Craig, H., Abdo, R., Barr, K., Kerfoot, S., Dagnino, L., & Penuela, S. (2024). Global pannexin 1 deletion increases tumor‐infiltrating lymphocytes in the BRAF /Pten mouse melanoma model. Molecular Oncology. https://doi.org/10.1002/1878-0261.13596
Vancouver
Sanchez-Pupo RE, Finch GA, Johnston DE, Craig H, Abdo R, Barr K, et al. Global pannexin 1 deletion increases tumor‐infiltrating lymphocytes in the BRAF /Pten mouse melanoma model. Molecular Oncology. 2024. doi:10.1002/1878-0261.13596
BibTeX
@article{SanchezPupo2024,
author = {Sanchez-Pupo, Rafael E and Finch, Garth A and Johnston, Danielle E and Craig, Heather and Abdo, Rober and Barr, Kevin and Kerfoot, Steven and Dagnino, Lina and Penuela, Silvia},
title = {Global pannexin 1 deletion increases tumor‐infiltrating lymphocytes in the BRAF /Pten mouse melanoma model},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13596}
}
EUVIMED